ASPIRE-AR_US Tigecycline Landing Page
Pfizer is pleased to announce the 2012 ASPIRE Competitive Research Grant Awards: Broad Spectrum Antibiotics for the Treatment of Gram-Negative or Polymicrobial Infections: Clinical Evaluation in Complex Adult Patients
The mission of the ASPIRE Awards in Antibacterial Research is to advance the medical knowledge to better understand disease pathogenesis, risk factors, host response and treatment outcomes in adult patients.
Clinical data exists for tigecycline in a variety of patients with known infections. However, most of this information is from controlled clinical trials and patients with certain disease complexities are underrepresented.
Request for Proposals
Pfizer invites investigators to apply for the 2012 ASPIRE Awards in Antibacterial Research through submission of innovative research proposals that evaluate tigecycline’s role in the treatment of infections within approved indications.
2012 Research Topic
Broad Spectrum Antibiotics for the Treatment of Gram-Negative or Polymicrobial Infections: Clinical Evaluation in Complex Adult Patients
An applicant should have a strong academic career interest within the areas of focus and should consider the following components when developing their research proposals:
A. Clinical evaluations of tigecycline within the following disease states:
- Complicated intra-abdominal infections
- Complicated skin and skin structure infection
- Community-acquired bacterial pneumonia
B. Clinical evaluations of tigecycline within the following patient populations:
- Age > 55 years
- Renal insufficiency
- Pulmonary comorbidities
- Critically ill
- Vascular disease
- Thermal Injury
C. The following patient populations and infection types are EXCLUDED:
- Nosocomial pneumonia including Ventilator-Associated Pneumonia
- Diabetic Foot Infections
- Treatment of Clostridium difficile
- Impact on intestinal microflora
Within the specified patient populations with infection types of interest, investigators are expected to:
- Generate exploratory clinical data in patients receiving tigecycline to better understand disease pathogenesis, risk factors, host response and treatment outcomes
- Be able to complete the research in 12 months
- Present and/or publish the results of the study
Well-designed retrospective analyses are preferred however, small pilot studies that attempt to test hypotheses will be considered as long as the study can be completed within 1 year.
Investigators may consider evaluating additional clinical measures (e.g. length of stay, readmission, ventilator days, etc.). However, proposals seeking to financially quantify outcomes are outside the scope of the program. See website FAQ’s for guidance.
Pfizer is funding awards from $50,000 USD to a maximum of $100,000 USD* (including direct costs, institutional overhead costs, and indirect costs) each for one year to conduct research generating data that will lead to a better understanding of the safety and efficacy of tigecycline in complex patients within approved indications.
*Please note that study budgets will be evaluated separately to ensure the requested funding is commensurate with the work proposed.
Deadline for Application
Applications must be received by 11:59pm EST on April 24, 2012.